Intech Biopharm Corporation (6461.TWO)
TWD 26.4
(-1.31%)
TWD 26.4
(-1.31%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -204.13 Million | -190.38 Million | -200.6 Million | -167.37 Million | - |
| Net Income | -337.98 Million | -327.87 Million | -301.75 Million | -250.37 Million | - |
| Depreciation & Amortization | 84.81 Million | 85.35 Million | 85.29 Million | 84.94 Million | - |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | 14.12 Million | 16.88 Million | 10.63 Million | 4.29 Million | - |
| Change in working capital | 5.27 Million | 13.57 Million | -14.53 Million | -22.47 Million | - |
| Other non-cash items | 29.21 Million | 21.12 Million | 18.68 Million | 16.08 Million | - |
| Investing Cash Flow | -235.97 Million | -203.97 Million | -35.51 Million | -42.2 Million | - |
| Investments in PPE | -30.2 Million | -11 Million | -21.3 Million | -48.15 Million | - |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -210 Million | -195 Million | -15 Million | - | - |
| Sales/Maturities of investments | - | - | - | 5 Million | - |
| Other Investing Activities | 4.05 Million | 65 Thousand | -60 Thousand | 231 Thousand | -38 Thousand |
| Financing Cash Flow | 453.02 Million | 238.7 Million | 251.92 Million | 242.13 Million | - |
| Debt repayment | -25 Million | -254.9 Million | -30 Million | -258.73 Million | - |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 460 Million | 5.06 Million | 300 Million | - | - |
| Other Financing Activities | 201 Thousand | 427 Thousand | 122 Thousand | - | 143 Thousand |
| Accounts receivables | 231 Thousand | - | - | - | - |
| Accounts payables | -1.01 Million | - | - | - | - |
| Inventory | 9.36 Million | 6.55 Million | -4.26 Million | -12.55 Million | - |
| Other working capital | -4.31 Million | - | - | - | - |
| Cash at beginning of period | 64.81 Million | 220.48 Million | 204.68 Million | 172.12 Million | - |
| Cash at end of period | 77.72 Million | 64.81 Million | 220.48 Million | 204.68 Million | - |
| Capital Expenditure | -30.2 Million | -11 Million | -21.3 Million | -48.15 Million | - |
| Effect of forex changes on cash | 1000.00 | -4000.00 | -3000.00 | 12 Thousand | - |
| Net cash flow / Change in cash | 12.91 Million | -155.66 Million | 15.79 Million | 32.56 Million | - |
| Free Cash Flow | -234.34 Million | -201.38 Million | -221.91 Million | -215.53 Million | - |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -92.62 Million | -74.9 Million | -98.19 Million | -337.98 Million | -85.86 Million | -72.77 Million |
| Depreciation & Amortization | 22.07 Million | 21.34 Million | 21.14 Million | 84.81 Million | 21.11 Million | 21.31 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 2.3 Million | 2.18 Million | 8.5 Million | 14.12 Million | 1.11 Million | 2.07 Million |
| Change in working capital | -8.93 Million | -2.64 Million | -5.04 Million | 5.27 Million | 12.74 Million | 7.89 Million |
| Other non-cash items | 6.77 Million | 6.98 Million | 6.79 Million | 29.21 Million | 7.77 Million | 7.34 Million |
| Investing Cash Flow | 246.37 Million | -15.8 Million | -302.27 Million | -235.97 Million | -13.96 Million | 38.47 Million |
| Investments in PPE | -20.51 Million | -17.71 Million | -3.75 Million | -30.2 Million | -14.76 Million | -2.59 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | -210 Million | -210 Million | - | - |
| Sales/Maturities of investments | 265 Million | - | - | - | - | 40 Million |
| Other Investing Activities | 60 Thousand | 20 Thousand | - | - | - | - |
| Financing Cash Flow | -89.61 Million | 72.84 Million | 371.19 Million | 453.02 Million | 19.1 Million | -9.87 Million |
| Debt repayment | -82 Million | -80 Million | -80 Million | -25 Million | -27 Million | -2 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | 460 Million | 460 Million | - | - |
| Other Financing Activities | -7.61 Million | 68 Thousand | - | 201 Thousand | - | - |
| Accounts receivables | 4.96 Million | - | - | - | - | - |
| Accounts payables | 6.16 Million | - | - | - | - | - |
| Inventory | -17.37 Million | 6.41 Million | -1.8 Million | 9.36 Million | 4.2 Million | -5.09 Million |
| Other working capital | -2.68 Million | - | - | - | - | - |
| Cash at beginning of period | 87.82 Million | 77.72 Million | 80.94 Million | 64.81 Million | 114.52 Million | 124.08 Million |
| Cash at end of period | 174.37 Million | 87.82 Million | 77.72 Million | 77.72 Million | 80.94 Million | 114.52 Million |
| Capital Expenditure | -20.51 Million | -17.71 Million | -3.75 Million | -30.2 Million | -14.76 Million | -2.59 Million |
| Effect of forex changes on cash | 36 Thousand | -17 Thousand | -19 Thousand | 1000.00 | 29 Thousand | -10 Thousand |
| Net cash flow / Change in cash | 86.54 Million | 10.1 Million | -3.21 Million | 12.91 Million | -33.58 Million | -9.55 Million |
| Free Cash Flow | -90.75 Million | -64.64 Million | -75.86 Million | -234.34 Million | -53.51 Million | -40.73 Million |
TR1
BIG
PECO
CDAB
6197
1223